UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2021



Aveanna Healthcare Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-40362 (Commission File Number)	81-4717209 (IRS Employer
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	Identification No.
400 Interstate North Parkway SE		
Atlanta, Georgia		30339
(Address of Principal Executive Offices)		(Zip Code)

Registrant's Telephone Number, Including Area Code: 770 441-1580

	(Former Name or Former Address, if Changed Since Last Report)							
Che	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:							
	☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)							
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act	(17 CFR 240.14a-12)						
	Pre-commencement communications pursuant to Rule 14d-2(b) unde	er the Exchange Act (17	7 CFR 240.14d-2(b))					
	Pre-commencement communications pursuant to Rule 13e-4(c) unde	er the Exchange Act (17	CFR 240.13e-4(c))					
	Securities regi	stered pursuant to Sec	ction 12(b) of the Act:					
		Trading						
	Title of each class	Symbol(s)	Name of each exchange on which registered					
	Common Stock, par value \$0.01 per shar	AVAH	The NASDAQ Stock Market LLC					
	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).							
Em	erging growth company \square							
	n emerging growth company, indicate by check mark if the registrant h ounting standards provided pursuant to Section 13(a) of the Exchange		e extended transition period for complying with any new or revised financial					

Item 7.01 Regulation FD Disclosure.

On August 23, 2021, Aveanna Healthcare Holdings, Inc. (the "Company", "we", "us", or "our") made available a financial presentation to investors for a series of one on one investor meetings. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on our website at ir.aveanna.com.

Use of our Website and Social Media to Distribute Material Company Information

We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on the "Investors" section of www.aveanna.com. We also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the "Investors" section of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K.

The information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Aveanna Investor Presentation - August 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,	the registrant has duly	caused this report to	be signed on its behalf b	by the undersigned	hereunto duly
authorized.					

AVEANNA HEALTHCARE HOLDINGS INC.

Date: August 23, 2021 By: /s/ David Afshar

David Afshar Chief Financial Officer (Principal Financial and Accounting Officer)



Disclaimers and Forward-Looking Statements



This investor presentation (this "presentation" and any oral statements made in connection with this presentation are for information purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of Aveanna Healthcare Holdings Inc. (including its consolidated subsidiaries, "Aveanna," the "Company," "we," "us" or "our"). The information charmed forevirus internal and external source believed to be reislable, but there can be no assurance as to the accuracy or completeness of such information. Any data on past performance contained herein is not an indication as to future performance. Except as required by applicable law, Aveanna assumes no obligation to update the information in this presentation. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. The communication of this presentation is restricted by law and it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No representation or warranty (whether express or implied) has been made by Aveanna with respect to the matters set forth in this presentation.

Gautionary Note Regarding Forward-Looking Statements.

Certain matters discussed in this presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this Certain matters discussed in this presentation constitute forward-looking statements within the meaning of the Private Secunities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements generally can be identified by the use of terminology such as "believe," expect," "anticipate," "intend," "plan," "stimuta," "say," "should," "predict," "project," "project

Industry and Market Data

Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable, but we have not independently verified the accuracy of this information. Any industry forecasts are based on data (including third-party data), models and experience of various professionals and are based on various assumptions, all of which are subject to change without notice. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in "Cautionary Note Regarding Forward-Looking Statements." These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

This presentation includes various performance indicators and non-GAAP financial measures that we use to help us evaluate our business, identify trends affecting our business, formulate business plans, and make strategic decisions. EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Field contribution, Field contribution margin, Adjusted corporate expense and pro forma presentations of the foregoing are financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Reconciliations of such non-GAAP measures to their nearest comparable GAAP measures can be found in the Appendix to this presentation or contained in Avaenans's filings with SEC, which can be viewed on the SECs bestler, www.sec.gov, and on Aveanans's website, www.avaenans.com. Any non-GAAP financial measures used in this presentation are in addition to, and not meant to be considered superior to, or a substitute for, the Company's financial statements prepared in accordance with GAAP.

Additional information with respect to Aveanna is contained in its filings with the SEC and is available at the SEC's website, www.sec.gov, and on Aveanna's website, www.aveanna.com



Today's Presenters

YEARS IN HOME HEALTH / HEALTHCARE







Tony Strange Chief Executive Officer



David Afshar Chief Financial Officer

15+



Jeff Shaner Chief Operating Officer

30+

Services in 2006 for \$454 million

Former Vice Chairman and later

Health Services, acquired by Kindred Healthcare in 2015

PSA Healthcare since 2015

for \$1.8 billion

Executive Chairman of

 Executive Chairman of Aveanna Healthcare since 2017

Executive Chairman of Gentiva

 Founded Healthfield in 1986, acquired by Gentiva Health Former President of Healthfield, acquired by Gentiva in 2006

- for \$454 million

 Former CEO and Board Member of Gentiva Health Services, acquired by Kindred Healthcare in 2015 for \$1.8 billion
- Chief Executive Officer of PSA Healthcare since 2015
- Chief Executive Officer of Aveanna Healthcare since 2017
- Inspections Leader with the Public Company Accounting Oversight Board
- Former CFO of ApolloMD
- Chief Financial Officer of Aveanna Healthcare since 2018

20+

- Former VP of Operations of Healthfield, acquired by Gentiva Health Services in 2006
- Former President of Gentiva Health Services' Hospice Division
- Former SVP, President of Operations of Gentiva Health Services
- Chief Operating Officer of PSA Healthcare since 2015
- Chief Operating Officer of Aveanna Healthcare since 2017



Aveanna at a Glance





^{1. 2021} forecast based on previously provided earning guidance posted in our August 11. 2021 earnings release. 2. 2021 proforms revenue based on 2021 revenue guidance plus \$22.9 million revenue for Ductor's Choice generated during the period in 2021 prior to acquisition. 3. Represents 2016A revenue of the predecessor, PSA. 4. Pro Forms for acquisition completed in 2020.

OUR CULTURE

OUR MISSION

To revolutionize the way homecare is delivered, one patient at a time.











CORE VALUES

Compassion

Team Integrity

Inclusion

Trust

Innovation

Compliance

Fun

VHO WE ARE



OPERATING PRINCIPLES

The Five "C"s

Census Growth

Clinical Outcomes

Customer Satisfaction

Cost Control

Cash Collection

HAT WE DO



Who We Serve





"Having our Aveanna care team means less hospital visits, more consistent care and a partnership between me and her Aveanna nurses. Together, we keep Brylee home and in her best health."

Private Duty Services



"Melia's progress has been amazing since coming home with Aveanna's enteral nutrition and nursing services. You can see in her eyes what it means to her to be with family. Playing and laughing with her sisters is what Melia wakes up for every day."

Medical Solutions



"I loved meeting the nurses and therapists who came to my home. They were caring, encouraging and so helpful with my recovery. Now I am independent again and feeling great after my hip replacement surgery."

Home Health & Hospice

Private Duty Services Segment



"By Th	e Numbers"					
Financial Highlights	Key Operati	ing Statistics				
\$1,399mm	185					
Run Rate Revenue ¹	Locations					
29% — 30%	22	29,000				
Gross Margin²	States	Patients on Service				
4% - 5%	<10	3-5 Years				
Organic Growth Rate ³	Avg. Patient Age	Avg. Case Length				

Key Items

- Growth Drivers Advanced clinical recruiting, experienced sales force, density in key geographies, leading clinical care and a strong technology platform
- Public Metrics Hours, revenue rate, cost of revenue rate and spread
- Reimbursement Profile Heavily weighted Medicaid and Medicaid MCO, hourly reimbursement based on physician plan of care and authorizations



- MOne nurse One Patient
- Fee for Service Billed by the hour
- Full Time & Per Diem
 Caregivers paid by the hour
- >> Longer Length of Stay
- Demand exceeds Supply



1. Flux Palle Revenue based upon Q2 2021 Annualized, 2, Management's expectation of gross margin percentages over time. 3, Management's expectation of total organic revenue growth rate over time.

Medical Solutions Segment



"By The	e Numbers"	
Financial Highlights	Key Operati	ng Statistics
\$145mm Run Rate Revenue¹		5 ations
43% — 45% Gross Margin ²	19 States	26,000 Patients on Service
9% - 11% Organic Growth Rate ³	Mixed Avg. Patient Age	2-3 Years Avg. Case Length

Key Items

- Growth Drivers Clinically-specialized sales force, scaled infrastructure, new market expansion strategy, cross-sell between PDS and HHH
- Public Metrics Unique patients served, reimbursement rate and cost of revenue per unique patient served
- Reimbursement Profile Commercial and Medicaid reimbursement based on caloric intake proscribed by physicians



- Nutritional Support Enteral Product, Equipment and Supplies
- Provided to Pediatrics, Adults, and Seniors
- Monthly Distribution Services
- Longer Length of Stay



1. Run Rate Revenue based upon Q2 2021 Annualized. 2. Management's expectation of gross margin percentages over time. 3. Management's expectation of total organic revenue growth rate over time

ें

Home Health & Hospice Segment



"By Th	e Numbers"							
Financial Highlights	Financial Highlights Key Operating Statistics							
\$200mm	65							
Run Rate Revenue ¹	Locations							
47% - 49%	15	7,200						
Gross Margin ²	States	Patients on Service						
7% - 9%	78	100 Days						
Organic Growth Rate ³	Avg. Patient Age	Avg. Case Length						

Key Items

- Growth Drivers superior clinical outcomes and star ratings, experienced sales force, specialty programs targeting highcost patient populations, meaningful investments in scalable infrastructure
- Public Metrics Total admissions, episodic admissions, total episodes and revenue per episode
- Reimbursement Profile Medicare and commercial payers based on fee for service and episodic payment structure



Home Health

- Seriatric Patient Population
- Short-term Intermittent Services
- Episodic Reimbursement
- Shorter Length of Stay

Hospice

- Primarily Geriatric Patient Population
- Shorter Length of Stay
- End-of-Life Care



^{1,} Rour Rite Revenue based upon Q2 2021 Annualized which includes acquisiblens from 5 Points, Recover, and Doctors Choice., 2, Management's expectation of gross margin percentages over time. 3, Management's expectation of total organic revenue growth rate over time.

Leverageable Corporate Infrastructure




Continued Leveraging of Corporate OH

Leverage core competencies in nurse recruiting, training and retention

IT infrastructure including recruiting, business intelligence, scheduling and RCM applications and patient facing devices


Overlapping RCM needs utilizing Aveanna's RCM capabilities

Continued leverage of corporate overhead through M&A and organic growth



1. See definition of adjusted corporate expenses provided in our August 11, 2021 earnings release. Reconciliation found in the appendix

Large, Fragmented Home Care Markets Support Sustainable Growth



Source: Third party consulting report, management estimates.

National Providers vs. Local Competitors

Public Peers









- · Multibillion-dollar companies
- · Comprised of mostly Home Health and Hospice
- Makes up ~8% of TAM

Local / Regional Competitors

- \$25M \$150M companies
- Local and regional presence
- · Long history of establishing themselves in the market
- · Traditionally grown organically over time
- · Makes up ~85% of TAM

Source: Third party consulting report, management estimates,

Large Private Peers








- \$500M Multibillion-dollar companies
- Mix of traditional Homecare, PDN, and Therapy
- Makes up ~7% of TAM

TAM Breakout



Industry Trends

Current and Future Trends

Value-Based Care

- Establish risk-bearing arrangements that reward Aveanna's scale and capabilities
- Well-positioned to benefit from shift to value-based care due to our scale, technology infrastructure, clinical training and compliance programs

Senior Population Growth

- Every day in the U.S., 10,000 people turn 65
- Continued increase in life expectancy

Medical Technology Advancements

 Continued advancements are allowing medically fragile children to increase their life expectancy


Positive Rate Environment

- National and State reimbursement rate increases continue
- Investments increasing in Home Care to treat highest cost, most complex cases, from newborns to elderly
- Shift to preferred home setting continues


Source: Third party consulting report, management

Cost Savings

Daily Cost of PDN



Daily Cost of Adult Home Health



Reimbursement Environment is Structurally Positive

Diverse group of payers includes managed care organizations ("MCO's"), state-based Medicaid programs, Medicare, MA plans, commercial insurance and other government payers across 30 states

Stability of PDN Rates¹

Key Stats¹

- > Over 1,500 distinct payers
- No single payer accounted for more than 11% of revenue in 2021
- Diversified across 30 states
- In PDN, reimbursement rates have increased 1.5% per year on average from 2015 - 2021
- In past three years, 20 states had positive PDN rate increases while only one state reduced rates by more than 1%

Patients viewed as "protected population"




Services are essential, lifesustaining care



Represents ~1.6% of total Medicaid expenditures



Demand exceeds supply, pressuring payers to reimburse at adequate rates



1. Management Data. 1. Payer mix for Q2 2021.

Sophisticated Platform to Source, Execute and Integrate Acquisitions

Since 2017, Aveanna has completed 11 transactions1 which have all been integrated or are being integrated into the company.



Management Team has Significant M&A Track Record

- Management team has executed more than 50 acquisitions comprising >\$6bn of transaction value over last 30 years.
- Aveanna has completed 11 transactions¹ since 2017.

Aveanna Acquisitions























Aveanna has a robust pipeline of potential acquisitions targets, which we continue to actively develop and evaluate.

Integration Management Office (IMO) Truly Differentiates

Dedicated IMO Team



16 people exclusively dedicated to integrating acquisitions

- Led by Derik Reynecke, SVP of Corporate Development & Integration, with over 15 years of M&A, integration and operational experience
- More than 57 years of healthcare-related deal structuring, due diligence, integration, operations and functional experience
- Ability to integrate multiple transactions at the same time

Detailed M&A Diligence



The IMO team leads due diligence across all functions

- Manages integration risks (Operational, Cultural, Legal, Technology, Billing, Clinical and Compliance)
- Verifies quality of revenue and earnings, compliance and regulatory standards, and clinical product
- Locates value creation opportunities
- Identifies key integration areas

Integration Playbook



A disciplined, phased integration approach built on "seek to understand" and "do no harm"

- Clearly defined time and milestonebased integration goals
- Focused communication and change management events
- Tracking and monitoring costs and value captured
- Conduct improvement analysis for future integrations



Combined, the IMO Team has conducted diligence on, closed, and integrated more than 38 transactions in the Home Health, Hospice, Private Duty Nursing and Medical Solutions industries.

Diversified, Accretive M&A Strategy

EXAMPLE 1 Aveanna's M&A strategy is designed to unlock significant strategic and financial value across both PDS and HHH markets, with significant value creation and multiple arbitrage opportunities.

⊗Annual expectations of \$150m - \$200m in additional revenue from acquisitions

M&A Value Drivers	Private Duty Service	Adult Home Health & Hospice
Cost Synergies	Eliminate acquired overhead	Eliminate acquired overhead
Clinical Labor Efficiencies	Improve recruitment	
Payer Scale & Relevance	Enhance contracting	
Cross-Sell of Existing Services	Drive enteral, therapy cross-sell	Drive enteral, therapy cross-sell
Diversification/ New Market Entry	Diversify payer mix	Diversify payer mix
Geographic Expansion	Enter new states with local scale	Leverage PDN licenses to drive de novos
M&A Engine	16 person M&A integration team, with multi-functional technology and decades of experience	I experience across sourcing, execution, operations,
Case Study Results:	3 Acquisitions	3 Acquisitions
2020 / 2021		
	\$78mm 2020 Revenue ¹	\$182mm 2020 Revenue ²

t. Equals the sum of 2020A revenue for Total Care, Preferred Pediatric Home Health Care and Evergreen Home Healthcare. 2. Equals the sum of 2020A revenue for Five Points Healthcare, Recover Health and Doctor's Choic



Methodical, Systematic Approach to Acquisition Integration

Proven M&A playbook perfected from extensive experience and enabled by scaled technology platform



Compelling Financial Profile



Track Record of Double-Digit Revenue & Adj. EBITDA Growth

- ☑ Revenue CAGR of 11.6% and Adj. EBITDA CAGR of 16.3% between 2018A and 2021F¹
- Mid single digit organic growth driven by scale advantages and de novo expansions



Highly Diversified and Stable Revenue Mix

- Highly diversified payer mix with no single payer accounting for more than ~11% of revenue²
- Robust growth from MS and HHH segments positioned to further diversify business mix



Stable Margin Profile

- ☑ Historically stable gross margins of ~30-33% driven by improving reimbursement and control of labor costs
- Platform infrastructure in place to drive operating leverage and efficiencies



Deep Pipeline of Inorganic Growth Opportunities

- ☑ Proven track record of accretive M&A, executing and integrating 11 transactions since 2017⁴
- Robust pipeline of potential acquisition targets that are actively developed and evaluated



Healthy Cash Flow Generation

- ✓ Strong operating cash generation opportunity resulting from IPO deleveraging and credit facility restructuring
- High total cash flow generation opportunity to fund acquisitions strategy and delever over time

1. 2021 forecast based on previously provided earnings guidance posted in our August 11, 2021 earnings release. 2. Represents metrics for 2020A. 3. Based on GAAP gross profit and GAAP revenue from 2018A to YTD Q2 2021A. 4. Includes the predecessors, Exist and PSA.

Proven Ability to Drive Robust Growth



See appendir for details on non-GAAP reconciliations. 1. Includes current year contribution of acquisitions completed in 2020 and 2021 (Total Car2/148/femed Pediatric Home HaRRS/fe, Evergment Home HaRRS/fe, Everyment HaRRS/fe,

Liquidity / Credit Statistics Overview

Aveanna's repayment of debt with IPO Proceeds and Credit Facility Amendment in July, 2021 significantly reduced leverage and reduced debt service going forward.

\$ in millions)	At Fiscal	Year-End	At Quarter-End			
100	2018	2019	2020	Q2 2021		
Cash	8	3	137	107		
Revolver Availability	53	24	55	180		
Total Liquidity	61	27	192	287		
	70 70			-		
Long-Term Debt	987	1.060	1 205	861		
Long-Term Debt Net Long-Term Debt	987 979	1,060 1,057	1,205 1,068	861 754		

	FIS	Fiscal Year-Ended				
	2018	2019	2020	Q2 2021		
Adjusted EBITDA	101	113	152	178		



Reconciliation of Corporate Expenses to Adjusted Corporate Expenses

	F	Y2018		FY2019	FY2020	1	LH2021
Corporate expenses		104,486		113,235	113,828		59,800
Non-cash share-based compensation		(2,018)		(1,782)	(3,032)		(4,825)
Sponsor fees (1)		(3,177)		(3,230)	(3,229)		(808)
Fees related to debt modification		575		-	(4,265)		7
Interest rate derivatives (2)		(92)		<u>U</u> 2	- W- <u>-</u>		2
Acquisition-related costs and other costs (3)		47.6		(5,821)	(2,226)		-
Integration costs (4)		(20,777)		(15,049)	(7,245)		(7,649)
Legal costs and settlements associated with acquisition matters (5)		(3,575)		(3,783)	(4,820)		(1,134)
COVID-related costs, net of reimbursement (6)		940		₩.	(1,832)		(221)
Other system transition costs, professional fees and other (8)		(467)		(1,164)	(5,322)		(3,726)
Total adjustments	\$	(30,106)	\$	(30,829)	\$ (31,971)	\$	(18,363)
Adjusted Corporate expenses	\$	74,380	\$	82,406	\$ 81,857	\$	41,437
Adjusted Corporate expenses as % of Revenue		5.9%	411	6.0%	5.5%		4.9%

^{1-8:} Please see our earnings release posted on August 11, 2021 for further description of the nature of these items